A Literature Review of COVID 19 Vaccination and Lichen Planus Pigmentosus: Is There a Correlation?

Authors

  • Marisa G. Ponzo MD-PhD, FRCPC North York Dermatology Clinic, Toronto, Ontario

Abstract

The global response to the COVID-19 pandemic involved rapidly developing and distributing various vaccines to curb the spread of the SARS-CoV-2 virus. While these vaccines are effective in preventing severe illness and hospitalization due to COVID-19, they have also prompted rigorous monitoring for potential side effects and adverse events. Among the vast array of reported post-vaccination side effects, the emergence or worsening of dermatological conditions has attracted significant attention from both clinicians and researchers. 

Author Biography

Marisa G. Ponzo MD-PhD, FRCPC, North York Dermatology Clinic, Toronto, Ontario

Dr. Marisa Ponzo is board certified in both the U.S. and Canada and is a community dermatologist in Toronto, Ontario. She completed her MD-PhD degree at McGill University followed by her dermatology residency at the University of British Columbia. She is currently working at North York Dermatology Clinic and has a busy medical, cosmetic and clinical trial practice. Prior to her recent move to Toronto, she was the Division Head of Dermatology at St Paul’s Hospital in Vancouver, BC. In addition, she ran specialty clinics, including the Medsafe clinic, where patients with severe cutaneous adverse reactions to medications were assessed, and their culprit drugs were identified through specialized testing. She also ran a skin cancer screening clinic for patients with solid organ transplants. 

References

Chaima K, Fatma H, Nadine K, Chahir K, Emna B, Khadija S, et al. Lichen planus pigmentosus post COVID‐19‐vaccination: a case report with literature review. Dermatol Ther. 2022;35(12):e15891. doi:10.1111/dth.15891

Ghosh A, Coondoo A. Lichen planus pigmentosus: the controversial consensus. Indian J Dermatol.2016;61(5):482-486. doi:10.4103/0019-5154.190108

Edek YC, Tamer F, Öğüt B. Lichen planus pigmentosus inversus with nail involvement following COVID‐19 vaccination: a case report. Dermatol Ther. 2022;35(11):e15809. doi:10.1111/dth.15809

Sun L, Duarte S, Soares-de-Almeida L. Case of lichen planus pigmentosus–inversus after Oxford–AstraZeneca COVID-19 vaccine: cause or coincidence? J Eur Acad Dermatol Venereol. 2022;36(7):e514-e516. doi:10.1111/jdv.18058

Aryanian Z, Balighi K, Azizpour A, Kamyab Hesari K, Hatami P. Coexistence of pemphigus vulgaris and lichen planus following COVID-19 vaccination. Case Rep Dermatol Med. 2022;2022:2324212. doi.org/10.1155/2022/2324212

Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: a systematic review and meta-analysis. Am J Clin Dermatol. 2016;17(1):11-22. doi: 10.1007/s40257-015-0160-6

Samycia M, Lin AN. Efficacy of topical calcineurin inhibitors in lichen planus. J Cutan Med Surg. 2012;16(4):221-229. doi: 10.1177/120347541201600403

Lim KK, Su WP, Schroeter AL, Sabers CJ, Abraham RT, Pittelkow MR. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin Proc. 1996;71(12):1182-1191. doi:10.4065/71.12.1182

Muthu SK, Narang T, Saikia UN, Kanwar AJ, Parsad D, Dogra S. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open label non-randomized prospective pilot study. Int J Dermatol. 2016;55(9):1048-1054. doi:10.1111/ijd.13293

Downloads

Published

2024-03-26

How to Cite

1.
Ponzo MG. A Literature Review of COVID 19 Vaccination and Lichen Planus Pigmentosus: Is There a Correlation?. Can Dermatol Today [Internet]. 2024 Mar. 26 [cited 2024 Apr. 27];5(1):32–34. Available from: https://canadiandermatologytoday.com/article/view/5-1-Ponzo

Issue

Volume 5, Issue 1, March 2024

Section

Articles

Most read articles by the same author(s)